Viking Therapeutics

VKTX

Market cap $2.6B

Overview Fund Activity

23.09 USD

-0.60

2.53%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

23.45

+0.36

1.56%

1 day

-2.53%

5 days

-10.68%

1 month

-45.14%

3 months

-12.64%

6 months

-22.59%

Year to date

-43.85%

1 year

-63.31%

5 years

249.85%

10 years

288.07%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 49

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $231M | Put options by funds: $97.6M

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

42% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 59

38% more repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 107

10% more capital invested

Capital invested by funds: $1.84B [Q1] → $2.02B (+$179M) [Q2]

6% more funds holding

Funds holding: 369 [Q1] → 390 (+21) [Q2]

0.04% less ownership

Funds ownership: 67.87% [Q1] → 67.83% (-0.04%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

65% upside

Avg. target

$87

278% upside

High target

$122

428% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	$102	Buy Reiterated	19 Aug 2025
Raymond James Ryan Deschner	$122	Strong Buy Maintained	24 Jul 2025
Citigroup David Lebowitz	$38	Neutral Maintained	24 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 49 articles about VKTX published over the past 30 days

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Zacks Investment Research

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Viking Therapeutics, Inc. (VKTX) reached $24.09 at the closing of the latest trading day, reflecting a -2.92% change compared to its last close.

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

The Motley Fool

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard Health Care ETF.

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback

Zacks Investment Research

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Zacks Investment Research

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

24/7 Wall Street

5 Stocks Poised to DOUBLE Your Money by 2027

If you want to double your money over the next two years, investing in companies in booming industries with enormous tailwinds goes a long way. Of course, finding those companies is no easy task. But focusing on the industries in which they operate — such as artificial intelligence (AI), flying cars and quantum computing — can provide valuable insights.

5 Stocks Poised to DOUBLE Your Money by 2027

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.48, indicating a -5.56% shift from the previous trading day.

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

The Motley Fool

Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.

The market was less than impressed with the top-line results from Viking Therapeutics' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily centered on the oral formulation.

Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.

See News Rankings

Charts implemented using Lightweight Charts™